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A
 
BSTRACT
 
It is now widely accepted that aspirin, along with other
non-steroidal anti-inflammatory drugs (NSAIDs), may
precipitate asthma attacks in a minority of susceptible
individuals. The syndrome is part of a mucosal inflam-
matory disease that typically affects the nasal, as well
as the bronchial, mucosa and sometimes the gut and
skin also. Although the mucosal cellular infiltrate in
aspirin-sensitive asthma and rhinitis resembles that
of asthma and rhinitis in general, there is evidence of
increased expression of asthma-relevant cytokines,
such as interleukin-5 and granulocyte–macrophage
colony stimulating factor, and a more intense infiltrate
of mast cells and eosinophils. One key feature of
aspirin-sensitive asthma is thought to be the over-
production of cysteinyl leukotrienes, principally by
these local mast cells and eosinophils, but whether this
represents a fundamental abnormality or is simply a
consequence of greater numbers and activation of
inflammatory cells is unclear. Genetic polymorphisms
of the leukotriene C
 
4
 
 synthase gene, which result in
elevated expression of this enzyme, may also play a
role. In addition, overexpression of cysteinyl leuko-
triene receptors, particularly CysLT
 
1
 
, may contribute to
an enhanced response of local inflammatory and
structural cells to cysteinyl leukotrienes. Aspirin chal-
lenge in these patients is accompanied by acute further
elevation of the already elevated baseline cysteinyl
leukotriene synthesis, a phenomenon that is most
closely related to the ability of aspirin and related
NSAIDs to inhibit the cyclooxygenase enzyme COX-1.
The reason for this is unknown, although it has been
suggested that the COX-1 product prostaglandin E
 
2
 
(PGE
 
2
 
) serves as a ‘brake’ to leukotriene synthesis and
that somehow this mechanism is deficient in aspirin-
sensitive asthmatics. A better understanding of the
pathogenesis of aspirin-sensitive asthma will undoubt-
edly lead to better approaches to treatment. Aside
from the use of drugs that inhibit cysteinyl leukotriene
synthesis or block the action of cysteinyl leukotrienes
on their receptors, recent data suggest that PGE
 
2
 
, and
possibly lipoxin analogs, may also prove effective in
the treatment of aspirin-sensitive asthma.
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I
 
NTRODUCTION
 
The phenomenon of aspirin-sensitive asthma, first
described by Widal 
 
et al.
 
1
 
 and then extended by Samter
and Beers,
 
2
 
 is characterized by a syndrome of asthma
and/or rhinitis precipitated by exposure to aspirin and
related non-steroidal anti-inflammatory drugs (NSAIDs).
Asthma, rhinitis or both may be prominent clinical
features and the disease may also affect the mucosa of
the gastrointestinal tract and the skin, causing gastro-
intestinal upset and urticaria/angioedema on aspirin
exposure.
 
3
 
 Aspirin sensitivity is seen in approximately
10% of adult asthmatics and commonly begins in middle
age. The disease is slightly more common in females,
but there is no relationship with the atopic diathesis.
 
4
 
Aspirin-sensitive asthmatics are over-represented in
those presenting with life-threatening severe asthma
attacks.
 
5,6
 
Although the mechanism of aspirin sensitivity in
asthma remains unclear, most investigators are agreed
that the reaction to aspirin is not immunologically medi-
ated. There is no evidence of an IgE response to aspirin
and these patients do not have positive aspirin skin prick
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tests. The fact that the effect of aspirin is mimicked by
a wide variety of other NSAIDs also makes the scenario
of immunological cross-reactivity extremely unlikely. In
addition, there appears to be no abnormality of bio-
availability or metabolism of aspirin in these patients.
 
7
 
Because of this, the diagnosis of aspirin sensitivity can
only be made objectively by experimental challenge.
Current studies suggest that aspirin-sensitive asthma is
most likely to be related to abnormal eicosanoid meta-
bolism, both overproduction of the cysteinyl leukotrienes
and increased expression of their receptors, and abnor-
malities of prostanoid metabolism, which may be further
modified by drugs, such as aspirin, that inhibit cyclo-
oxygenases. The purpose of this paper is to summarize
the field to date based on studies in our own and other
laboratories.
 
R
 
OLE
 
 
 
OF
 
 
 
CYSTEINYL
 
 
 
LEUKOTRIENES
 
Cysteinyl leukotrienes are formed by the action of
5-lipoxygenase (5-LO) and 5-LO-activating protein
(FLAP) on arachidonic acid released from cell mem-
brane phospholipids by the enzyme phospholipase A
 
2
 
(Fig. 1). This produces leukotriene (LT) A
 
4
 
, which is
hydrolyzed in neutrophils and monocytes to form LTB
 
4
 
and conjugated to glutathione in mast cells, basophils,
eosinophils and other cells by the enzyme LTC
 
4
 
 synthase
to form LTC
 
4
 
 and then enzymatically converted to LTD
 
4
 
and LTE
 
4
 
. The cysteinyl leukotrienes (LTC
 
4
 
/D
 
4
 
/E
 
4
 
) likely
contribute to bronchoconstriction, microvascular leakage
and elevated mucus secretion in asthma and rhinitis.
Their role in regulating local mucosal inflammation is
more controversial,
 
8
 
 but probably contributory. It has
been shown
 
9
 
 that inhaled LTE
 
4
 
 increases infiltration of
eosinophils into asthmatic airways, although this effect is
likely to be indirect because cysteinyl leukotrienes have
little direct chemotactic activity for eosinophils 
 
in vitro
 
.
Although therapy with leukotriene receptor antagonists
has been associated with a reduction in the numbers of
bronchial mucosal eosinophils in asthmatics, this effect
is not very marked in comparison with that of topical
glucocorticoids.
 
10
 
Increased production of cysteinyl leukotrienes is a
characteristic of asthma in general, with increased con-
centrations of the relatively stable end metabolite LTE
 
4
 
found in the urine, bronchoalveolar lavage fluid and
sputum of asthmatic patients.
 
11
 
 We and others
 
12,13
 
 have
shown that aspirin-sensitive compared with -tolerant
asthmatics have elevated urinary concentrations of LTE
 
4
 
at baseline. In addition, this elevated baseline leukotriene
production is further augmented for several hours follow-
ing aspirin challenge.
 
12–15
 
 A similar phenomenon is seen
in the nasal mucosa of aspirin-sensitive patients.
 
16,17
 
 We
have also demonstrated reduction in the urinary concen-
trations of LTE
 
4
 
 in aspirin-sensitive patients following
successful aspirin desensitization.
 
18
 
 Finally, we and others
have shown that treatment of aspirin-sensitive asthmatics
with leukotriene receptor antagonists results in improve-
ments in lung function, symptoms and quality of life,
 
19–21
 
although the response is not dramatic and may be quite
variable.
 
22
 
 Furthermore, these drugs protect against
acute aspirin challenge.
 
23
 
 Taken together, these studies
provide circumstantial, but very compelling, evidence for
a role for the cysteinyl leukotrienes in regulating the
severity of aspirin-sensitive asthma and that aspirin expo-
sure, at least in the short term, exacerbates asthma in
sensitive patients through elevated cysteinyl leukotriene
production.
 
E
 
NHANCED
 
 
 
PRODUCTION
 
 
 
OF
 
 
 
CYSTEINYL
 
 
 
LEUKOTRIENES
 
 
 
IN
 
 
 
ASPIRIN
 
-
 
SENSITIVE
 
 
 
ASTHMA
 
: 
T
 
HE
 
 
 
CHICKEN
 
 
 
OR
 
 
 
THE
 
 
 
EGG
 
?
 
Notwithstanding these observations, the question arises
whether elevated cysteinyl leukotriene production is a
cause, or a consequence, of increased bronchial
mucosal inflammation in aspirin-sensitive asthma. There
is some evidence that leukotriene synthesis is elevated
in these patients 
 
a priori
 
. For example, it has been
reported
 
24
 
 that the numbers of cells immunoreactive for
LTC
 
4
 
 synthase are significantly elevated in the bronchial
mucosa of aspirin-sensitive compared with aspirin-
tolerant asthmatics. There was some indication that this
immunoreactivity reflected enzyme activity in the sense
that a correlation was observed between the concentra-
tions of cysteinyl leukotrienes in the bronchoalveolar
lavage fluid of these patients and the numbers of LTC
 
4
 
synthase-immunoreactive cells. Furthermore, LTC
 
4
 
 syn-
thase expression in the aspirin-sensitive patients could
be correlated with their bronchial responsiveness to
soluble (lysine) aspirin challenge. In contrast, the total
numbers of cells expressing immunoreactivity for 5-LO
and FLAP, as well as LTA
 
4
 
 synthase, were not different in
the aspirin-sensitive and -tolerant patients. We similarly
reported no significant difference in the total numbers
of 5-LO-immunoreactive cells in aspirin-tolerant and
–sensitive asthmatics.
 
25
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Evidence has also been presented that the activity of
enzymes involved in leukotriene synthesis, particularly
LTC
 
4
 
 synthase, may be genetically regulated. The –444A/
C single nucleotide polymorphism allele, which lies in the
promoter region of the LTC
 
4
 
 synthase gene and may reg-
ulate its expression, has been associated with an elevated
risk of aspirin-sensitive asthma in some studies,
 
26
 
 but not
in others.
 
27
 
 In contrast, 30% of aspirin-sensitive asth-
matics do not have this allele and it is expressed in 25%
of aspirin-tolerant patients. Clearly, therefore, this allele
alone does not represent a unique pathophysiological
feature that separates aspirin-sensitive from -tolerant
asthmatics. Other, as yet unidentified, genetic regulatory
mechanisms may contribute. Similarly, although aspirin-
sensitive asthmatics have elevated concentrations of
urinary LTE
 
4
 
, there is a broad overlap with tolerant
patients, so that this cannot be used a diagnostic test.
 
13
 
There has been little study of the variability of leukotriene
production in the general population (although such dif-
ferences may only come to light in the context of inflam-
mation). Finally, a single heritable gene abnormality
resulting in abnormally elevated cysteinyl leukotriene
production does not, in common with all similar genetic
studies, readily explain why aspirin-sensitive disease may
be acquired, at least clinically, late in life.
An alternative explanation for the overproduction of
cysteinyl leukotrienes in aspirin-sensitive patients is that it
reflects unique sensitivity of the cells that produce them,
principally mast cells and eosinophils, to the effects of
aspirin and other salicylates, including dietary salicylates.
 
Fig. 1
 
Outline of eicosanoid metabolism. The net effect of the prostanoids is to reduce asthma severity, whereas that of the cysteinyl
leukotrienes (LTC
 
4
 
/D
 
4
 
/E
 
4
 
) is to increase it. This balance may be deranged in favor of increased leukotriene production and/or
reduced production or activity of prostaglandin (PG) E
 
2
 
 in aspirin-sensitive asthma. HETE, hydroxyeicosatetraenoic acid; LX, lipoxin;
LO, lipoxygenase; FLAP, 5-lipoxygenase-activating protein; COX, cyclooxygenase.
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Our own studies have demonstrated increased numbers
of eosinophils and mast cells in the bronchial mucosa of
patients with aspirin-sensitive asthma.
 
25
 
 Furthermore,
we  have shown that, following segmental bronchial
challenge of asthmatics with lysine aspirin, there is a sig-
nificant reduction in the numbers of mucosal tryptase-
positive mast cells in aspirin-sensitive compared with
aspirin-tolerant asthmatics,
 
28
 
 suggesting local direct acti-
vation and degranulation of mast cells. Such challenge
was also associated with increased mucosal infiltration of
activated eosinophils. Thus, direct activation of mast cells
and eosinophils by salicylates, one of the consequences
of which is elevated leukotriene production, may also
play a role in the regulation of disease severity in aspirin-
sensitive asthma. Surprisingly, the direct effects of aspirin
on mast cells and eosinophils in these patients have been
little explored.
Cytokines, particularly interleukin (IL)-5 and granulocyte–
macrophage colony stimulating factor (GM-CSF), are
involved in the activation, maturation and prolongation
of survival of eosinophils. We reported previously that
aspirin-sensitive compared with -tolerant asthmatics had
significantly elevated numbers of bronchial mucosal mast
cells and eosinophils expressing IL-5 and GM-CSF.
 
29
 
Other studies
 
30
 
 have produced similar findings. This local
enhanced production of eosinophil-active cytokines may
also contribute to increased cysteinyl leukotriene pro-
duction in aspirin-sensitive asthmatics. It has been shown,
for example, that IL-5 enhances the synthesis of cysteinyl
leukotrienes by eosinophils 
 
in vitro.
 
31
 
In view of all these observations, the question whether
or not aspirin-sensitive asthma is associated with a funda-
mental, predetermined abnormality in the production of
cysteinyl leukotrienes, as opposed to being merely an
expression of particularly severe disease caused by
unique sensitivity of granulocytes, such as mast cells and
eosinophils to aspirin exposure, remains open. These
possibilities are not, of course, mutually exclusive.
 
C
 
YSTEINYL
 
 
 
LEUKOTRIENE
 
 
 
RECEPTORS
 
 
 
IN
 
 
 
ASPIRIN
 
-
 
SENSITIVE
 
 
 
ASTHMA
 
The leukotrienes exert their actions on inflammatory
cells, mucosal capilliaries, mucus glands and smooth
muscle by interacting with specific receptors. G-Protein-
coupled receptors for LTB
 
4
 
 and the cysteinyl leukotrienes
have been characterized separately. So far, two recep-
tors for the cysteinyl leukotrienes, termed CysLT
 
1
 
 and
CysLT
 
2
 
, have been cloned.
 
32,33
 
 Both receptors bind to
LTC
 
4
 
, LTD
 
4
 
 and LTE
 
4
 
 with affinity order LTD
 
4
 
 > LTC
 
4
 
>> LTE
 
4
 
 (CysLT
 
1) and LTD4 = LTD4 >> LTE4 (CysLT2)
and both are expressed on bronchial smooth muscle
cells and inflammatory leukocytes. Because CysLT1
receptor antagonists ameliorate basal and aspirin-
provoked asthma in aspirin-sensitive asthmatics, it seems
very likely that at least some of the disease regulatory
actions of the cysteinyl leukotrienes are mediated
through this receptor. In a recent study,34 we showed
that the total number of cells, as well as the percentages
of total inflammatory leukocytes expressing the CysLT1
receptor, was significantly elevated in the nasal sub-
mucosa of patients with aspirin-sensitive compared with
aspirin-tolerant chronic rhinosinusitis. In contrast, the
percentages of total leukocytes expressing the LTB4
receptor did not differ significantly between the two
groups. We also found that topical nasal desensitization
of the aspirin-sensitive patients was associated with a
reduction in the numbers of nasal inflammatory cells
expressing CysLT1. These observations importantly
suggest that, in addition to overproduction of cysteinyl
leukotrienes, aspirin-sensitive asthma may also be asso-
ciated with overexpression of the CysLT1 receptor. This
may result in an increased sensitivity of aspirin-sensitive
asthmatics to the effects of exogenous leukotrienes. For
example, inhaled LTE4 increases bronchial inflammation
in asthmatics9 and this process may be further aug-
mented in aspirin-sensitive asthma if the responding
inflammatory cells overexpress CysLT1. We have shown35
that aspirin-sensitive asthmatics are hyperresponsive
compared with tolerant patients to the bronchoconstric-
tor effects of inhaled LTE4. Again, this may putatively
reflect overexpression of cysteinyl leukotriene receptors
on bronchial smooth muscle in these patients. It will be
vital to extend these studies on rhinosinusitis to the
bronchial mucosa of aspirin-sensitive and -intolerant
asthmatics. Such studies are now in progress in our
department.
The CysLT2 receptor resembles the CysLT1 receptor in
terms of its ability to mediate calcium influx in transfected
cells and binds to all three cysteinyl leukotrienes with
similar affinity (see above). Although characterized
pharmacologically predominantly so far on human pul-
monary venous smooth muscle, previous studies suggest
that the CysLT2 receptor is also expressed in lung paren-
chyma, as well as on inflammatory leukocytes.33 Our
preliminary studies of the nasal submucosa of patients
with aspirin-sensitive rhinosinusitis showed clear expres-
sion of the CysLT2 receptor on inflammatory leukocytes,
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epithelial cells and glands, although, in contrast with
CysLT1, expression of CysLT2 was not significantly differ-
ent in the aspirin-sensitive compared with -tolerant
patients. Nevertheless, these observations suggest a
possible role for CysLT2 receptors in mediating some of
the disease regulatory effects of cysteinyl leukotrienes in
aspirin-sensitive asthma and, indeed, in asthma in gen-
eral. This may encourage the further development of
drugs such as BAY u9773, which antagonizes both CysLT
receptors.
A final small enigma relates to the actions of exoge-
nous leukotrienes on asthmatic subjects in vivo. As men-
tioned, we have shown35 that aspirin-sensitive asthmatics
show bronchial hyperresponsiveness to LTE4, but not LTD4
or LTC4. Other studies9 have similarly shown that inhaled
LTE4, but not LTD4, increases bronchial inflammation in
subjects with asthma. In view of the pharmacologically
defined differential sensitivity of both the CysLT1 and the
CysLT2 receptors for LTC4/D4/E4 ligands (see above), it is
difficult to understand why LTE4, but not LTD4 or LTC4,
produces such effects if they are mediated through the
CysLT1 or CysLT2 receptors. One may speculate that
inflammation may have altered post-receptor signaling,
resulting in differential regulation in a ligand-specific fash-
ion. Alternatively, it is possible that there are further cys-
teinyl leukotriene receptors that remain to be discovered.
ROLE OF PROSTANOIDS IN ASPIRIN-SENSITIVE 
ASTHMA
Arachidonic acid is a substrate for the production of
both leukotrienes and prostanoids (Fig. 1). Prostanoids
are manufactured by the enzyme cyclooxygenase (COX),
which exists in two isoforms, termed COX-1 and COX-2,
which are encoded by distinct genes. Both enzymes
conjugate with a peroxidase to form the enzyme pros-
taglandin H2 (PGH2) synthase. Cyclooxygenase inhibitors
prevent this association. Cyclooxygenase-1 is expressed
constitutively in most mammalian cells and is probably
responsible for the physiological production of prosta-
noids that regulate many normal body processes. In
contrast, COX-2 is inducible and is generally expressed
only in the context of ongoing inflammation. We36 and
others24,37 have shown that the numbers of cells showing
immunoreactivity for COX-2 are increased in the
bronchial mucosa of asthmatics compared with controls,
but that COX-2 expression is not particularly elevated in
aspirin-sensitive compared with -tolerant asthmatics,
either at baseline or following aspirin challenge.
The ability of drugs to exacerbate symptoms in aspirin-
sensitive asthmatics is directly related to their COX-1
inhibitory activity.38,39 Inhibitors of COX-1 induce acutely
elevated local and systemic leukotriene release in these
patients.14,18,40 The time-honoured but somewhat naïve
concept that COX-1 inhibitors ‘divert’ arachadonic acid
metabolism away from prostanoid synthesis and towards
leukotriene synthesis has been refined. In particular, there
is good evidence for a specific role for the prostanoid
PGE2 in ameliorating aspirin-induced asthma. For exam-
ple, in these patients, exogenous PGE2 blocks aspirin-
induced bronchoconstriction, elevated urinary LTE4
concentrations and release of cysteinyl leukotrienes from
cultured peripheral blood leukocytes.41,42 Prostaglandin
E2 also regulates 5-LO activity43 and inhibits mast cell
degranulation. In animal ‘models’ of asthma, targeted
deletion of the COX-1 or COX-2 genes increases inflam-
matory influx into the airways following ovalbumin chal-
lenge, again underlining the significant role of COX-1/2
products in limiting airway inflammation.44 Some
products of COX-1/2, such as PGD2 and PGF2α, are in
contrast proinflammatory, or at least cause broncho-
constriction, so presumably these effects reflect a summa-
tion of the action of several, potentially antagonistic
prostanoids.
Inhibition of COX-1, leading to reduced PGE2 produc-
tion, thus constitutes one mechanism for COX-1 inhibitor-
induced exacerbation of asthma, but the key question is
why this phenomenon is not observed in all asthmatics,
but only in those who are aspirin sensitive. It is possible to
speculate that the COX enzymes are differentially suscept-
ible to aspirin inhibition in aspirin-sensitive and -tolerant
patients, but there is no evidence for a mechanism for this
and no evidence of polymorphism of the relevant genes.
Alternatively, aspirin and related drugs may have other
effects on the COX enzymes not directly related to the
inhibition of the production of prostanoids.45 Another
possibility is that the COX-1/2 enzymes are the same in
aspirin-sensitive and -tolerant asthmatics, but the former
patients are particularly dependent upon the tonic inhibi-
tion of cysteinyl leukotriene generation by the action of
PGE2 on target cellular receptors. This may reflect a rela-
tive deficiency of PGE2 production, abnormality of PGE2
receptor expression or both. There are two studies in the
literature suggesting that PGE2 production may be
deficient in aspirin-sensitive patients. In the first,46 epithe-
lial cell monolayers outgrown using hormones from
resected nasal polyps produced slightly but significantly
less PGE2 after 6 days of culture in vitro in aspirin-sensitive
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compared with -tolerant patients. In the second study,47
fibroblasts outgrown from bronchial biopsies (2–3 weeks
of culture) produced less PGE2 in response to 18 h of
stimulation with cytomix (lipopolysaccharide/IL-1α/tumour
necrosis factor-α) in aspirin-sensitive compared with
-tolerant patients, although spontaneous production was
equivalent. In both studies, cells from aspirin-sensitive
and -tolerant patients showed no differential sensitivity to
suppression of PGE2 production by exogenous COX-1
inhibitors. Consequently, the evidence that aspirin-
sensitive asthmatics are deficient in PGE2 synthesis, or
that this process is more susceptible to aspirin inhibition
in aspirin-sensitive patients, is currently limited. Further-
more, the hypothesis that PGE2 deficiency is a fundamen-
tal problem in aspirin-sensitive asthma does not sit well
with the observation that selective COX-2 inhibitors,
which presumably also reduce PGE2 production,48 do not
appear to increase leukotriene production and broncho-
spasm in these patients.49 As an alternative to the defi-
cient production of PGE2, an alternative hypothesis is that
these patients may show a deficiency of PGE2 receptor
expression on target leukocytes and other tissues, which
may result in deficient PGE2 ‘braking’ of cysteinyl leuko-
triene production at baseline, which is further exagger-
ated by COX-1 inhibition.
There are four G-protein-coupled PGE2 receptors des-
ignated EP1–4.50 Whereas EP2 and EP4 receptors activate
adenylate cyclase and increase cAMP, EP3 generally
couples to Gi and reduces cAMP, although recently
described splice variants of EP3 may conversely elevate
cAMP in the presence of high concentrations of agonist.51
Thus, there is plenty of scope for variability in the
responses of target cells to PGE2 according to the spec-
trum of receptors they express. The receptors EP1, EP3,
and EP4 are widely expressed in human cells, including
inflammatory leukocytes, mast cells and smooth
muscle.50,51 There are very few reports addressing the
expression of PGE2 receptors on inflammatory leukocytes
in the human lung and, as yet, none in the context of
aspirin-sensitive asthma. In a preliminary study of nasal
biopsies from patients with aspirin-sensitive chronic
rhinosinusitis, we have obtained unequivocal evidence of
staining with antibodies to all four EP receptors. The cells
stained included leukocytes, glandular cells, epithelial
and endothelial cells, with a clearly distinct staining
pattern in each case. In these sections, we noted
increased global expression of EP1 and EP2, but not EP3
and EP4, in the nasal mucosa of patients with rhino-
sinusitis compared with controls, although there were no
significant differences at this level between aspirin-
sensitive and -tolerant subjects. Examination of receptor
expression on individual inflammatory cells is, at present,
in progress.
OTHER PRODUCTS OF THE LIPOXYGENASE 
PATHWAYS
Apart from leukotrienes, there are other recognized
products resulting from the action of lipoxygenase
enzymes. The best described are 15S-hydroxyeicosa-
tetraenoic acid (15S-HETE) and the lipoxins (LX). 15S-
Hydroxyeicosatetraenoic acid is generated by direct
metabolism of arachidonic acid by 15S-LO, whereas LX
are double lipoxygenase products formed through the
enzymatic action of both 5-LO and 15-LO. There is little
information about the role of 15S-HETE in asthma,
although there is increasing interest in the biology of the
LX.52 A recent report suggests that peripheral blood
leukocytes, when exposed to aspirin, produce more
15S-HETE in aspirin-sensitive compared with aspirin-
tolerant, patients.53 Conversely, the production of LX and
15-epimer LX was elevated in aspirin-tolerant compared
with -sensitive asthmatics.54 This suggests that LX may be
‘protective’ or ‘anti-inflammatory’. Further support for
this idea has come from a murine model of asthma with
transgenic leukocyte expression of human LXA4 recep-
tors. In this model, administration of a stable LXA analog
blocked allergen-induced airway responsiveness and
inhibited lung inflammatory cell infiltration and local
cytokine, as well as prostanoid and cysteinyl leukotriene
production.55 Studies in humans with LX analogs are
now needed to further define the role of these potentially
important eicosanoid mediators in aspirin-sensitive
asthma and, indeed, in asthma in general.56
IMPLICATIONS FOR FUTURE MANAGEMENT
Despite the strong scientific rationale for the use of
antileukotriene drugs in aspirin-sensitive asthma, these
have not had the impact on day-to-day therapy of these
patients that may have been expected. Although several
clinical trials have confirmed that they improve lung
function and quality of life, there is a variability of
response between patients.19–22
With the advent of highly selective COX-2 inhibitors,
which appear, so far, to be relatively safe in aspirin-
sensitive asthmatics,49 a requirement to tolerize these
patients to aspirin so that they can receive aspirin and
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related COX-1 inhibitors for their anti-inflammatory and
analgesic effects has become less of a priority (although it
should be noted that COX-2 inhibitors do not exert the
antiplatelet effects of aspirin and, therefore, are not suit-
able for the prophylaxis of stroke or myocardial infarction).
As a therapeutic strategy, aspirin desensitization still
bears scrutiny. In a typical desensitization regimen, small
incremental oral doses of aspirin are ingested over the
course of a few days until 650 mg aspirin is tolerated.
This dose is then maintained daily. If doses are increased
still further, typically to 650 mg twice daily, patients often
experience some improvement in their chronic asthma
and rhinitis. In a recent long-term study of patients treated
in this manner,57 after 1 year of continuous aspirin treat-
ment patients experienced highly statistically significant,
but clinically rather small, improvements in nasal symp-
toms and requirements for inhaled and topical nasal
corticosteroid doses. There was a more useful reduction
in exposure of these patients to short courses of oral
prednisolone for asthma exacerbations. Approximately
one-third of patients ‘failed’ desensitization, either because
of the development of intolerable unwanted effects or
because the procedure was ineffective.
Given that the precise mechanism of aspirin intoler-
ance is unknown, it is no surprise that the precise mecha-
nism of aspirin desensitization is also very unclear. We18
have shown that desensitization does not completely
abrogate production of LTE4 detectable in the urine, but
does blunt the acute asthmatic response to further aspirin
challenge. Aspirin desensitization also reduces bronchial
responsiveness to exogenous leukotriene, a phenome-
non that may reflect, at least partly, downregulation of
CysLT1 receptors on mucosal inflammatory cells (see
above).34 Finally, it should not be forgotten that aspirin is
a potent anti-inflammatory drug in its own right and very
high doses of aspirin may exert other anti-inflammatory
effects on the asthma process: for example, it has been
shown that aspirin can inhibit the activation of signal
transducers and activators of transcription (STAT) 6 by
IL-4 and IL-13 in vitro.58
In view of our preliminary evidence for the expression
of both CysLT1 and CysLT2 receptors in the respiratory
mucosa of patients with aspirin-sensitive rhinosinusitis
and given the fact that CysLT2 receptors have already
been implicated in mediating some of the effects of the
cysteinyl leukotrienes on tissue such as airways smooth
muscle,59 there may be a rationale, as mentioned pre-
viously, for the further development of combined antag-
onists of both CysLT1 and CysLT2 receptors, such as
BAY u9773. Against this is the observation that treatment
of aspirin-sensitive asthmatics with 5-LO inhibitors, which
should theoretically completely prevent the production
of cysteinyl leukotrienes and, thus, obviate the problem
of blocking leukotriene receptors, has not shown such
remarkable clinical advantages as may have been
expected over the CysLT1 leukotriene receptor antag-
onists,60 although a recent trial61 showed that treatment
of patients with the 5-LO inhibitor zileuton produced
improvement in nasal symptoms and improved non-
specific bronchial hyperresponsiveness, as well as
aspirin-induced bronchoconstriction.
Looking slightly further into the future, it is possible that
stable analogs of inhibitory prostanoids, such as PGE2, as
well as LX, may also prove useful for the treatment of
aspirin-sensitive asthma.
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